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Background: Magnetic resonance imaging (MRI) guided wire localization presents several challenges apart from
the technical difficulties. An alternative to this conventional localization method using a wire is the radio-guided
occult lesion localization (ROLL), more related to safe surgical margins and reductions in excision volume. The
purpose of this study was to establish a safe and reliable magnetic resonance imaging-radioguided occult lesion
localization (MRI-ROLL) technique and to report our initial experience with the localization of nonpalpable breast
lesions only observed on MRI.
Methods: Sixteen women (mean age 53.2 years) with 17 occult breast lesions underwent radio-guided localization
in a 1.5-T MR system using a grid-localizing system. All patients had a diagnostic MRI performed prior to the
procedure. An intralesional injection of Technetium-99m macro-aggregated albumin followed by distilled water was
performed. After the procedure, scintigraphy was obtained. Surgical resection was performed with the help of a
gamma detector probe. The lesion histopathology and imaging concordance; the procedure’s positive predictive
value (PPV), duration time, complications, and accuracy; and the rate of exactly excised lesions evaluated with MRI
six months after the surgery were assessed.
Results: One lesion in one patient had to be excluded because the radioactive substance came back after the
injection, requiring a wire placement. Of the remaining cases, there were four malignant lesions, nine benign
lesions, and three high-risk lesions. Surgical histopathology and imaging findings were considered concordant in all
benign and high-risk cases. The PPV of MRI-ROLL was greater if the indication for the initial MR examination was
active breast cancer. The median procedure duration time was 26 minutes, and all included procedures were
defined as accurate. The exact and complete lesion removal was confirmed in all (100%) patients who underwent
six-month postoperative MRI (50%).
Conclusions: MRI-ROLL offers a precise, technically feasible, safe, and rapid means for performing preoperative MRI
localizations in the breast.
Keywords: Magnetic resonance imaging (MRI), MR-guided interventional procedures, Nuclear medicine,
Radioisotopes, Breast cancer* Correspondence: fephila@gmail.com
1Department of Radiology, Federal University of Rio de Janeiro, Rua Prof.
Rodolpho Paulo Rocco 255, Cidade Universitária, Rio de Janeiro, RJ
21941-617, Brazil
2Department of Breast Imaging, Clínica de Diagnóstico por Imagem (CDPI),
Av. Ataulfo de Paiva 669, 2nd floor, Leblon, Rio de Janeiro, RJ 22440-032,
Brazil
Full list of author information is available at the end of the article
© 2013 Philadelpho Arantes Pereira et al.; licen
terms of the Creative Commons Attribution L
use, distribution, and reproduction in any medsee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly cited.
Philadelpho Arantes Pereira et al. BMC Medical Imaging 2013, 13:33 Page 2 of 9
http://www.biomedcentral.com/1471-2342/13/33Background
Magnetic resonance imaging (MRI) of the breast has
proven to be a valuable complement to the conventional
techniques, including mammography, ultrasonography,
and physical examination, for breast cancer detection, diag-
nosis, staging, and treatment follow-up [1]. In addition,
MRI is able to detect lesions that are not visible on these
conventional techniques in 10-39% of cases [2]. In patients
with proven breast cancer, MRI can detect additional ipsi-
lateral cancer sites in 6-34% of cases and unsuspected
contralateral cancer in 4-24% of cases [3-5]. However, as
the reported specificity of breast MRI (37–97%) is lower
than its high sensitivity (94-100%), suspicious lesions
detected by MRI must be confirmed histologically [3].
When suspicious, enhancing breast lesions are detected
solely with MRI, MRI-guided biopsy techniques are used
for accurate sampling of the lesions and for histopatho-
logical analysis. MRI-guided tissue sampling of these
“MRI-only observed lesions” can be accomplished by
needle localization followed by surgical excision, by MRI-
guided large-core needle biopsy, or through vacuum bi-
opsy [1,6]. For an interventional procedure to be clinically
useful, factors such as safety, accuracy, availability,
cost, patient preference, and surgeon’s request should
be considered [7]. MRI-guided needle localization is a
well-known and widely utilized technique for tissue
sampling, especially for breast lesions that are difficult
to access [1,6-8].
Until now, MRI-guided needle localization has been
performed through the deployment of a wire. While the
accuracy of needle and wire placement is important with
any means of guidance, it is particularly important for
MRI-guided procedures because lesion retrieval cannot
be verified with radiography of the lumpectomy speci-
men, as the lesion is commonly only visible in vivo after
the intravenous administration of a gadolinium-based
contrast material [9]. Although excisional biopsy after
MRI-guided wire localization has proven to be a suc-
cessful method for obtaining adequate material for
pathological evaluation, this technique is associated with
several challenges apart from the technical difficulties
[10-12], including the accordion effect, which leads to a
final wire position that is not the ideal after breast de-
compression; wire displacement and migration; wire
breakage; difficulties related to establishing surgical ac-
cess to the lesion; infection; and bleeding. Nevertheless,
its main disadvantage is the high incidence of residual
disease (up to 51% at the biopsy site) [12-15].
An alternative to this conventional localization method
using a wire is the radio-guided occult lesion localization
(ROLL), which consists of an intratumoral injection of
Technetium-99m (Tc-99m) macro-aggregated albumin
(MAA). On the day of surgery, a portable gamma probe
guides the biopsy, providing a practical and precisemethod for locating the intratumor injection site. In the
last years, this technique has been proposed by many
different studies as being the best option for the
localization of non-palpable breast lesions guided by
mammography or ultrasonography [12,16-19], resulting
in correct localization in more than 90% of cases. It has
also been associated with a higher prevalence of safe sur-
gical margins, improved cosmetic outcome, and less
postoperative pain, in addition to reductions in excision
volume and more accurate lesion centricity within the
surgical specimen [7,12-20].
Although ROLL has been used for more than 10 years
for mammography- and ultrasonography-guided locali-
zations, to the best of our knowledge, there is only one
study in the literature describing the use of radioactive
substances in MRI-guided localizations using a different
technique than the one described here [7]. Hence, this
study was designed to establish a safe and reliable tech-
nique and to report our initial experience with MRI-
ROLL of nonpalpable breast lesions only observed on
MRI.
Methods
Study population and lesion characteristics
From May 2011 to July 2012, this study prospectively
enrolled 16 women with 17 breast lesions. One lesion in
one patient was excluded from the study because the
procedure was unsuccessful, and a wire was required. As
a result, the study included 15 patients (age range, 38–
78 years; mean age, 53.3 years) with 16 breast lesions.
All patients had a diagnostic MRI performed prior to
the procedure, showing lesions not identified by mam-
mography or ultrasonography, even by “second look”
ultrasonography. The size range of these 16 lesions was
0.6-4.0 cm (median, 1 cm). Eleven lesions (68.75%) were
located in the left breast, and five lesions (31.25%) were
located in the right breast.
The ACR BI-RADS-MRI Lexicon was used to classify
the morphological and dynamic characteristics of the le-
sions [21]. Eight of the 16 lesions (50%) were non-mass
enhancement-type lesions, and the remaining eight (50%)
were mass-type lesions. From the eight non-mass en-
hancement lesions, three showed focal distribution, three
ductal distribution, one segmental distribution, and one
linear distribution. From the eight mass lesions, six had
oval shape and smooth margins, one had a lobulated
shape and smooth margins, and one had irregular shape
and margins. Most lesions had either moderate or early
marked enhancement. The delayed enhancement pattern
analyzed in the mass lesions showed plateau curves in
three out of the eight lesions and washout curves in the
remaining five lesions. The BI-RADS classifications were
BI-RADS 4 for 14 of the 16 lesions and BI-RADS 3, which
signifies a likely benign lesion, for 2 of the 16 lesions.
Philadelpho Arantes Pereira et al. BMC Medical Imaging 2013, 13:33 Page 3 of 9
http://www.biomedcentral.com/1471-2342/13/33Indications for the previous MRI examinations were
problem-solving in nine cases, a present history of ipsilat-
eral or contralateral breast cancer in three cases, a previous
personal history of breast cancer in one case, search for an
occult primary tumor in one patient with an altered axillary
lymph node, and integrity of breast implants in two cases.
Our institutional review (CEP HUCFF/FM) board ap-
proved the study, and all patients gave their informed
consent.
MRI-ROLL technique
All MRI-ROLL were performed by one of three radiologists
(FPAP, GM, MJGC) who were experts in breast imaging,
including MRI-guided breast procedures, using a 1.5-T MR
System (Signa Excite HD, GE Healthcare, Milwaukee, WI)
with the patient positioned prone in a dedicated 8-channel
breast coil. The breast undergoing localization was placed
in the coil using a grid-localizing system. First, the medial
aspect of the breast was positioned flush against a compres-
sion plate or a grid, depending on whether the access to
the lesion was lateral or medial, respectively. A lateral grid
or compression plate, also depending on whether the access
was lateral or medial, respectively, was then firmly adjusted
to fully compress and immobilize the breast. A vitamin E
capsule was used as a fiducial marker and was taped to the
grid over the expected lesion site, which was determined
based on review of the diagnostic MR images.
First, a localizing sequence was acquired, and the vol-
ume of interest was selected to include the compression
device and the vitamin E marker. Then, a sagittal T1-
weighted 3D fat-suppressed gradient-echo sequence (flip
angle, 15°; bandwidth, 41.67 MHz; matrix size, 220 ×
220; field of view, 220 mm; number of excitations, 1;
slice thickness, 2 mm; intersection gap, 0 mm) was re-
peated before and after the rapid bolus injection of 0.1
mmol/L of gadoterate meglumine (Dotarem, Guerbet,
Roissy, France) per kilogram of body weight, followed by
20 mL of saline, until the enhancing lesion was visual-
ized. The acquisition time, which was approximately
1 min per sequence, varied depending on the size of the
breast and the area covered.
The images were reviewed. A cursor was placed over
the lesion on the monitor, and its relationship to the
skin surface and the vitamin E marker was determined
by manually scrolling through sequential sagittal slices.
The grid of the compression device was evident as low-
signal-intensity lines on the skin surface due to pressure
indentation. The plastic of the compression device was
not visible on MRI. The vitamin E capsule was identified
as an area of high signal intensity on the skin surface.
The skin entry site was determined based on visual as-
sessment of the location of the lesion with respect to the
grid lines using the vitamin E capsule as a guide. The
depth of the lesion from the skin surface was calculatedas the difference between the depth of the skin surface
and the depth of the sagittal slice containing the lesion.
After calculating the entrance site and lesion depth, the
patient was withdrawn from the magnet. The skin overly-
ing the lesion was marked, and the skin was cleansed with
alcohol and anesthetized with 1–2 mL of 1% lidocaine
hydrochloride (Xylocaine, Astra USA, Westborough, MA).
A needle guide block (Needle block, In Vivo, Gainesville,
FL) was inserted into the grid hole overlying the anesthe-
tized area. A needle guide with 20-gauge holes was used to
anchor and stabilize the needle and to allow insertion of
the needle in a straight perpendicular fashion, thereby re-
ducing needle angulation during insertion. The MR-
compatible needle (20 ga, MRI-compatible needle, EZEM,
Westbury, NY) was then placed in the hole of the needle
guide closest to the skin marking. We inserted the needle
to the desired depth, taking into account the 1.5-cm thick-
ness of the needle guide.
Sagittal and axial T1-weighted 3D fat-suppressed
gradient-echo sequences were then obtained to docu-
ment the location of the needle, with the desired depth
of the tip optimally positioned within the lesion. The
needle was evident as a low-signal-intensity structure
with an adjacent susceptibility artifact. If the needle was
too deep or too superficial, adjustments were made.
When the needle tip was within the lesion or at least
within 5 mm of the lesion, a sagittal fat-suppressed T2-
weighted fast spin-echo sequence (repetition time/echo
time, 2300/102 ms; bandwidth, 35.7 MHz; matrix size,
256 × 224; field of view, 230 mm; number of excitations,
4; slice thickness, 2 mm; intersection gap, 0 mm; and ac-
quisition time, 1.46 minutes) was repeated before and
after the injection of the radioactive substance (Tc-99m
MAA). The injected dose was 1 mCi or 37 MBq if the
surgery had been performed the same day as the
localization or 4 mCi or 148 MBq if the surgery had
been performed the day after, followed by the adminis-
tration of 1 mL of distilled water. In this sequence, the
needle is also evident as a low-signal-intensity structure
with an adjacent susceptibility artifact. In contrast, the
water injected after the radioactive substance is evident
as a high-signal-intensity area and confirms the injection
of the radioactive material in the proper location within
the lesion. The subtraction technique was also used as a
control for the radioactive substance injection. The T2-
weighted sequence obtained before the radioactive ma-
terial plus water administration was subtracted from the
T2-weighted sequence obtained after the radioactive
substance plus water administration, and the high-signal-
intensity area from the injected water was better visual-
ized. The needle was then removed.
Immediately after localization, scintigraphy (Ventri, GE
Healthcare, Milwaukee, WI) was performed to serve as a
control for the presence of the radioactive substance; a
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MA) was also performed to serve as a road map for the
surgeon. We were aware that the radioactive substance
would not appear on the mammographic images. The re-
port and the images obtained from the MRI localization
and from the scintigraphic and mammographic control
were sent to the surgeon along with the patient. A six-
month follow-up MRI was suggested in the report to con-
firm lesion removal, mainly for benign cases.
During the surgery, a gamma probe (Johnson & Johnson,
New Jersey, NY) was used to locate the maximum radio-
active focus and, thus, the lesion. The complete removal of
the lesion was confirmed by the absence of radioactivity in
the breast tissue and by the presence of safe surgical mar-
gins. The excised tissue was sent for histopathological
examination.
MRI analysis and data collection
Histopathological characteristics of the lesion were de-
termined from the surgical pathology reports and were
categorized as benign, malignant, or high-risk. MR im-
aging and histopathological findings were reviewed and
considered concordant if the histopathological findings
provided an explanation for the imaging features, par-
ticularly in the benign and high-risk lesions. The positive
predictive value (PPV) of MRI-ROLL was defined as theFigure 1 A 78-year-old woman with invasive ductal carcinoma (IDC) o
sequence shows a regular mass in the upper inner quadrant of the right b
reveals the lesion with the needle, low-signal-intensity dot, inside (arrow). (
tip close to the lesion (arrow). (d) Sagittal fat-suppressed T2-weighted sequ
contrast-enhanced sequences (arrow). (e) Sagittal T2-weighted sequence a
water reveals a high-signal-intensity area and confirms that the radioactive
sequence subjected to subtraction technique: the high-signal-intensity area
control reveals the presence of the radioactive substance (arrow).number of cancers identified during MRI localization
divided by the total number of lesions that had under-
gone MRI localization. The PPV was also analyzed
according to the indication of the previous MRI examin-
ation, i.e., the MRI that first showed the lesion.
Breast MRI-ROLL cases were reviewed to assess the
procedure time (total magnet time), complication rate,
and accuracy. The procedure accuracy was measured by
the distance between the needle tip and the target lesion
prior to the injection of the radioactive material, by the
presence of high-signal-intensity area on T2-weighted se-
quence and on the subtracted images in the exact location
of the lesion after the water administration, and by the
presence of the radioactive material in the scintigraphic
control. The rate of exactly excised lesions was evaluated
on the MRI obtained six months postoperatively.
Data were collected and analyzed on a computerized
spreadsheet (Excel, Microsoft, Redmond, WA).
Results
Histopathological findings
A total of four malignant lesions (25%), all invasive
ductal carcinomas (IDC), were verified upon histopatho-
logic examination. The median size of the malignant le-
sions was 0.85 cm (range, 0.6-1.2 cm). The first carcinoma
was an oval-shaped mass with smooth margins, whichf the right breast. (a) Sagittal T1-weighted contrast-enhanced
reast (arrow). (b) Sagittal T1-weighted contrast-enhanced sequence
c) Axial T1-weighted contrast-enhanced sequence shows the needle
ence shows the exact location of the lesion after correlation with the
fter injection of Tc-99m MAA followed by injection of 1 mL of distilled
material is in the exact location of the lesion. (f) Sagittal T2-weighted
from the water injected is visualized better (arrow). (g) Scintigraphic
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phase and was classified as BI-RADS 3 (Figure 1). The
second, third, and forth carcinomas were non-mass-
enhancement masses with linear, focal, and focal distri-
butions, respectively (Figure 2); all three were classified
as BI-RADS 4 (Tables 1 and 2).
There were nine benign lesions (56.25%) with the fol-
lowing classifications: fibroadenoma (n = 2), columnar cell
alteration without atypia, apocrine metaplasia, adenosis
(n = 2), focal florid ductal hyperplasia (n = 2), nodular
florid adenosis (n = 1), intramammary lymph node (n = 1),
and fat necrosis (n = 1). The median size of the benign
lesions was 1.0 cm (range, 0.8-4.0 cm) (Tables 3 and 2).
Additionally, there were three high-risk lesions (23.1%)
with the following classifications: intraductal papilloma
(n = 1), fibroadenoma with atypia (n = 1), and atypical
ductal hyperplasia (n = 1). The median size of the high-risk
lesions was 0.6 cm (range, 0.6-2.8 cm) (Tables 4 and 2).
After revision, surgical histology and MR imaging find-
ings were considered concordant in all benign and high-
risk cases.
The PPV of MRI-ROLL was 25% (4/16). Importantly,
the PPV was greatest if the indication for the initial MR
examination was a current history of breast cancer (3/4 =
75%). Among the three carcinomas diagnosed on MRI-
ROLL in women with synchronous cancer, the cancersFigure 2 A 38-year-old woman with invasive ductal carcinoma (IDC) o
sequence shows a focal nonmass enhancement in the upper inner quadra
enhanced sequence reveals the lesion with the needle, low-signal-intensity
shows the needle tip close to the lesion (arrow). (d) Sagittal T2-weighted s
the contrast-enhanced sequences (arrow). (e) Sagittal fat-suppressed T2-we
distilled water reveals a high-signal-intensity area and confirms that the ra
T2-weighted sequence subjected to subtraction technique: the high-signa
(arrow). (g) Scintigraphic control reveals the presence of the radioactive suthat had MRI localization were in the ipsilateral breast in
one case and in the contralateral breast in two cases
(Table 1).
Procedure time, complications, accuracy, and follow-up
The median duration time to perform MRI-ROLL was
26 minutes (range, 20–37 minutes). No complications
occurred during any of the interventions. However, one
case had to be excluded because a hematoma formed
during the needle placement and the radioactive sub-
stance came back after the injection, requiring a wire
placement. Therefore, this study achieved technical suc-
cess in 16/17 (94.1%) of the cases.
The tip of the needle was placed within the lesions in
12 of the 16 cases (75%) and within 0.3 cm of the edge
of the lesions in the remaining four cases (25%) prior to
the radioactive material injection. Because the high-
signal-intensity area observed on the T2-weighted se-
quence and on the subtracted images was present in the
exact location of the lesion after the water administra-
tion and the scintigraphic control, the radioactive mater-
ial was confirmed to be present in all cases.
Exact and complete lesion removals were confirmed in
all cases (100%) that underwent MRI six months postop-
eratively, i.e., eight of the 16 cases (50%). Four patients
(25%) did not have MRIs because their surgeries hadf the right breast. (a) Sagittal T1-weighted contrast-enhanced
nt of the right breast (arrow). (b) Sagittal T1-weighted contrast-
dot, inside (arrow). (c) Axial T1-weighted contrast-enhanced sequence
equence shows the exact location of the lesion after correlation with
ighted sequence after injection of Tc-99m MAA followed by 1 mL of
dioactive material is in the exact location of the lesion. (f) Sagittal
l-intensity area from the water injected can be visualized better
bstance (arrow).
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Focal nonmass enhancement 1.0 4
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the study. The remaining four patients (25%) did not
undergo MRI because the surgeon did not request it.Discussion
Here, we present the technique and results of MRI-
ROLL of suspicious breast lesions only observed on
MRI. In total, we successfully performed MRI localizations
of 16 breast lesions in 15 patients. Although ours was a
small series, the findings suggest that this localization
technique is rapid, technically successful, and accurate,
without the challenges of MRI-guided wire localization.
In our study, the PPV of MRI-ROLL was 25%, which
is similar to the PPV of MRI-guided wire localization
[7]. The overall ratio of benign to malignant biopsies
among MRI-detected lesions ranges between 1:1 and 3:1,
depending on diagnostic criteria and indications, e.g., in
case of a personal or a family history of breast cancer,
invasive procedures are likely to be more frequently in-
dicated [2,11]. In our study, carcinoma was revealed in
women with known cancer who had been referred for
MRI-guided localization for preoperative staging. Of the
four carcinomas identified, one was classified as BI-
RADS 3 and three as BI-RADS 4. In addition, the three
BI-RADS 4 lesions exhibited morphology and enhance-
ment characteristics that were not specific for malig-
nancy. Even without suspicious characteristics, lesions in
a patient with a present history of ipsilateral or contra-
lateral breast cancer should be investigated and biopsied.
Our actual MRI-ROLL time was similar to the 15–59
minute time range that has been previously reported forTable 2 BI-RADS classification and histopathological
findings
Malignant Benign High-risk Total
BI-RADS 3 1 0 1 2
BI-RADS 4 3 9 2 14
Total 4 9 3 16MRI-guided wire localization [9-11]. With more experi-
ence, we expect to perform procedures faster and utilize
fewer sequences, while maintaining a high success rate.
Although we did not experience complications during
the procedures, we did not succeed in one case and had
to exclude it from our study. In that particular case, a
hematoma formed during placement of the needle; due
to the pressure caused by the hematoma, the radioactive
substance could not be injected properly, therefore re-
quiring wire placement. Injection of the radioactive sub-
stance may also be challenging when the lesion is harder
or more compact.
Currently, the added benefit of MRI in the detection of
clinically, mammographically, and ultrasonographically
occult cancers is well known. Cancers that are only truly
visible on MRI are detected in 14-35% of patients who
undergo breast MRI for a variety of reasons [9]. One of
the most frequently used methods for sampling MRI-
detected lesions remains needle localization with a wire,
either because it provides a better approach to breast le-
sions that are difficult to access or because it is less ex-
pensive and more available than other MRI biopsy
methods. Although excisional biopsy after MRI-guided
wire localization has proven to be a successful method
for obtaining adequate material for pathological evaluation,
the technique is associated with several disadvantages, in-
cluding technical difficulties for the interventional radiolo-
gist and the surgeon, thereby limiting the success rate of
the procedure and increasing the surgery duration time [2].
A potential problem with MRI-guided wire localiza-
tions is that the breast is compressed during the deploy-
ment of the wire but not during the surgical excision
[11]. This deployment creates an accordion effect. The
accordion effect has been a recognized explanation for
partly excised or missed lesions after MRI-guided needle
localizations [2,9,11,22,23]. The accordion effect in MRI-
ROLL is not a considerable problem because the radio-
active substance is injected on or very close to the lesion
and does not change position when the compression is
released. Wire displacement or migration between
localization and surgery has been recognized in the MRI
Table 3 Benign histopathological findings based on patient age, MRI indication, breast density, and MRI lesion
characteristics
Histopathological findings Age MRI indication Breast density Morphological and dynamic




Columnar cell alteration without
atypia, apocrine metaplasia,
adenosis
57 Integrity of breast
implants
Heterogeneously dense Segmental nonmass
enhancement
3.3 4
Columnar cell alteration without
atypia, apocrine metaplasia,
adenosis
60 Problem-solving Heterogeneously dense Ductal nonmass enhancement 1.6 4




Ductal nonmass enhancement 4 4





Irregular shape and margins
mass, type 3 curve
1 4
Nodular florid adenosis 42 Problem-solving Heterogeneously dense Oval shape and smooth margins
mass, type 3 curve
1 4
Focal florid ductal hyperplasia 56 Problem-solving Scattered fibroglandular
densities
Focal nonmass enhancement 1.8 4
Focal florid ductal hyperplasia 51 Problem-solving Scattered fibroglandular
densities
Lobulated shape and smooth
margins mass, type 3 curve
0.9 4




Oval shape and smooth margins
mass, type 3 curve
1 4
Fibroadenoma 57 Problem-solving Scattered fibroglandular
densities
Oval shape and smooth margins
mass, type 2 curve
0.8 4
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solves this problem.
There was no important difference between the cost of
the radioactive substance and the titanium wire. How-
ever, considering the surgical time, the preoperative wire
localization can result in a higher cost to the patient.
Confirmation of lesion retrieval remains an issue in
MRI-guided localization with a radioactive marker or a
wire. Because the lesion does not enhance ex vivo, there
is no possibility of direct verification that the correct
area has been excised [1]. Correlation of imaging and
histology plays an important role in this procedure, as in
breast biopsy with any method [10,11,24]. If the patho-
logical assessment yields a benign histology, review of
the original MRI and biopsy imaging is advised to re-
assess the level of suspicion and adequacy of sampling.
For cases that are felt to be discordant or possibly missed,
repeat biopsy or surgical excision is recommended as soon
as can be reasonably tolerated by the patient.Table 4 High-risk histopathological findings according to pat
characteristics
Histopathological findings Age MRI indication Breast density
Intraductal papilloma 51 Problem-solving Heterogeneously d
Fibroadenoma with atypia 52 Problem-solving Heterogeneously d
Atypical ductal hyperplasia 52 Problem-solving Heterogeneously dPostoperative MR imaging should be incorporated into
the routine follow-up of patients who have MR imaging-
guided localization to ensure lesion retrieval if the pro-
cedure yields benign findings and to assess for residual
tumor if the procedure reveals breast cancer. A study
analyzed postoperative MRI scans performed on 33 le-
sion sites, suggesting that the lesion was completely ex-
cised in 29 (87.9%), partly excised in three (9.1%), and
missed in one case (3.0%) [11]. Another study reported
13.5% inadequate removal of the lesion despite correct
needle positioning [2]. In our study, the exact and complete
lesion removal was confirmed in all cases (100%) that
underwent six-month follow up MRI. However, postopera-
tive MR imaging was not routinely performed, although it
was suggested to the surgeons in the procedure report. To
this point, only half of the cases have undergone postopera-
tive MRI.
Our study has some limitations. First, our series is
relatively small. The two main reasons for the study’sient age, MRI indication, breast density, and MRI lesion
Morphological and dynamic
characteristics of the lesions
Lesion size (cm) BI-RADS
ense Oval shape and smooth margins
mass, type 3 curve
0.6 4
ense Oval shape and smooth margins
mass, type 2 curve
0.6 3
ense Ductal nonmass enhancement 2.8 4
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be expensive, and MRI-ROLL is a new technique that is
not well known by mastologists. Further studies should
consider increasing the sample number to improve the
statistical power. Second, the water injected after the
radioactive substance in the target lesion is only ob-
served on MRI. Therefore, it is impossible to determine
the exact injection site using any other imaging modal-
ity. The same occurs in the single study published in the
literature regarding MRI-ROLL, in which the MRI con-
trast material injected after the radioactive material was
only observed on MRI [7]. The scintigraphy identifies
the radioactive material but does not reveal the exact in-
jection site. Further work in this area might also include
the injection of a radiographically visible marker within
the lesion in addition to the injected radioactive sub-
stance, e.g., an iodinated contrast or air [25], so that the
surgeon can see the location of the lesion with respect
to the nipple, the chest wall, and the remainder of the
breast tissue using mammography.
Conclusions
MRI-ROLL offers a relatively rapid and accurate means
for performing preoperative MRI-guided localizations in
the breast. The results of this preliminary study show
that MRI-ROLL is technically feasible and safe. This is
particularly important, as radio-guided surgery is easier
to perform, allows an effective lesion resection, and leads
to better cosmetic results. Larger studies and a compari-
son between the results of MRI-ROLL and MRI-guided
wire localization are needed before this technique can
become routine clinical practice.
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